ImmunityBio Inc (NASDAQ: IBRX)’s stock price has plunge by -15.68relation to previous closing price of 6.06. Nevertheless, the company has seen a -10.51% plunge in its stock price over the last five trading sessions. Schaeffers Research reported 2024-03-20 that Depending on who you ask, a recession is either right around the corner, or the stock market is ready to rattle off a seismic bull run.
Is It Worth Investing in ImmunityBio Inc (NASDAQ: IBRX) Right Now?
Moreover, the 36-month beta value for IBRX is 1.15. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IBRX is 136.93M and currently, short sellers hold a 40.00% of that float. On April 15, 2024, IBRX’s average trading volume was 4.09M shares.
IBRX’s Market Performance
The stock of ImmunityBio Inc (IBRX) has seen a -10.51% decrease in the past week, with a 0.59% rise in the past month, and a 28.72% gain in the past quarter. The volatility ratio for the week is 11.48%, and the volatility levels for the past 30 days are at 11.13% for IBRX. The simple moving average for the last 20 days is -8.99% for IBRX stock, with a simple moving average of 54.12% for the last 200 days.
Analysts’ Opinion of IBRX
Many brokerage firms have already submitted their reports for IBRX stocks, with Piper Sandler repeating the rating for IBRX by listing it as a “Neutral.” The predicted price for IBRX in the upcoming period, according to Piper Sandler is $4 based on the research report published on May 12, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see IBRX reach a price target of $8. The rating they have provided for IBRX stocks is “Buy” according to the report published on August 03rd, 2022.
IBRX Trading at 2.36% from the 50-Day Moving Average
After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.26% of loss for the given period.
Volatility was left at 11.13%, however, over the last 30 days, the volatility rate increased by 11.48%, as shares surge +4.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +52.08% upper at present.
During the last 5 trading sessions, IBRX fell by -10.51%, which changed the moving average for the period of 200-days by +95.04% in comparison to the 20-day moving average, which settled at $5.63. In addition, ImmunityBio Inc saw 1.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IBRX starting from BLASZYK MICHAEL D, who purchase 71,915 shares at the price of $2.75 back on Jun 05 ’23. After this action, BLASZYK MICHAEL D now owns 71,915 shares of ImmunityBio Inc, valued at $198,023 using the latest closing price.
Brennan John Owen, the Director of ImmunityBio Inc, purchase 25,000 shares at $2.83 during a trade that took place back on Jun 02 ’23, which means that Brennan John Owen is holding 25,000 shares at $70,700 based on the most recent closing price.
Stock Fundamentals for IBRX
Current profitability levels for the company are sitting at:
- -580.97 for the present operating margin
- -33.96 for the gross margin
The net margin for ImmunityBio Inc stands at -993.59. The total capital return value is set at -0.81.
Based on ImmunityBio Inc (IBRX), the company’s capital structure generated 3.29 points at debt to capital in total, while cash flow to debt ratio is standing at -0.43. The debt to equity ratio resting at -1.44. The interest coverage ratio of the stock is -6.11.
Currently, EBITDA for the company is -342.85 million with net debt to EBITDA at -1.71. When we switch over and look at the enterprise to sales, we see a ratio of 6530.74. The receivables turnover for the company is 0.2for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.05.
Conclusion
To wrap up, the performance of ImmunityBio Inc (IBRX) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
